Nguyen Uyen T, Harvey Hanjeong, Hogan Andrew J, Afonso Alexandria C F, Wright Gerard D, Burrows Lori L
Department of Biochemistry and Biomedical Sciences and the Michael G. DeGroote Institute for Infectious Diseases Research, McMaster University, Hamilton, Ontario, Canada.
Department of Biochemistry and Biomedical Sciences and the Michael G. DeGroote Institute for Infectious Diseases Research, McMaster University, Hamilton, Ontario, Canada
Antimicrob Agents Chemother. 2014 Nov;58(11):6508-17. doi: 10.1128/AAC.03671-14. Epub 2014 Aug 18.
Disinfectant-tolerant Listeria monocytogenes biofilms can colonize surfaces that come into contact with food, leading to contamination and, potentially, food-borne illnesses. To better understand the process of L. monocytogenes biofilm formation and dispersal, we screened 1,120 off-patent FDA-approved drugs and identified several that modulate Listeria biofilm development. Among the hits were more than 30 β-lactam antibiotics, with effects ranging from inhibiting (≤50%) to stimulating (≥200%) biofilm formation compared to control. Most β-lactams also dispersed a substantial proportion of established biofilms. This phenotype did not necessarily involve killing, as >50% dispersal could be achieved with concentrations as low as 1/20 of the MIC of some cephalosporins. Penicillin-binding protein (PBP) profiling using a fluorescent penicillin analogue showed similar inhibition patterns for most β-lactams, except that biofilm-stimulatory drugs did not bind PBPD1, a low-molecular-weight d,d-carboxypeptidase. Compared to the wild type, a pbpD1 mutant had an attenuated biofilm response to stimulatory β-lactams. The cephalosporin-responsive CesRK two-component regulatory system, whose regulon includes PBPs, was not required for the response. The requirement for PBPD1 activity for β-lactam stimulation of L. monocytogenes biofilms shows that the specific set of PBPs that are inactivated by a particular drug dictates whether a protective biofilm response is provoked.
耐消毒剂的单核细胞增生李斯特菌生物膜可在与食品接触的表面定殖,导致污染,并有可能引发食源性疾病。为了更好地了解单核细胞增生李斯特菌生物膜形成和分散的过程,我们筛选了1120种已过专利保护期的美国食品药品监督管理局(FDA)批准的药物,并鉴定出几种可调节李斯特菌生物膜发育的药物。筛选出的药物中有30多种β-内酰胺抗生素,与对照组相比,其对生物膜形成的影响范围从抑制(≤50%)到刺激(≥200%)。大多数β-内酰胺类药物还能使相当一部分已形成的生物膜分散。这种表型不一定涉及杀菌,因为某些头孢菌素的浓度低至其最低抑菌浓度(MIC)的1/20时,就能实现>50%的生物膜分散。使用荧光青霉素类似物进行青霉素结合蛋白(PBP)分析显示,大多数β-内酰胺类药物具有相似的抑制模式,只是刺激生物膜形成的药物不与PBPD1结合,PBPD1是一种低分子量的d,d-羧肽酶。与野生型相比,pbpD1突变体对刺激型β-内酰胺类药物的生物膜反应减弱。头孢菌素反应性CesRK双组分调节系统(其调控子包括PBPs)对该反应不是必需的。单核细胞增生李斯特菌生物膜的β-内酰胺刺激需要PBPD1的活性,这表明被特定药物灭活的特定一组PBPs决定了是否会引发保护性生物膜反应。